Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) and Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Volatility & Risk
Regulus Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Regulus Therapeutics and Supernus Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Regulus Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Supernus Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Earnings and Valuation
This table compares Regulus Therapeutics and Supernus Pharmaceuticals’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Regulus Therapeutics | $10.01 million | 3.15 | -$28.32 million | ($1.69) | -0.96 |
| Supernus Pharmaceuticals | $667.24 million | 2.50 | $60.71 million | $0.73 | 41.90 |
Supernus Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Regulus Therapeutics and Supernus Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Regulus Therapeutics | N/A | -85.37% | -63.50% |
| Supernus Pharmaceuticals | 6.84% | 4.86% | 2.68% |
Insider & Institutional Ownership
62.2% of Regulus Therapeutics shares are held by institutional investors. 8.4% of Regulus Therapeutics shares are held by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Supernus Pharmaceuticals beats Regulus Therapeutics on 8 of the 13 factors compared between the two stocks.
About Regulus Therapeutics
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
